Einzeltreffer — DigiBib

Background: Individuals with attention-deficit hyperactivity disorder (ADHD) often display over-response to stimuli that are irrelevant to the ongoing task, and their attentional abilities disproportionately worsen in the presence of competing stimuli. Auditory event-related potentials (ERPs) such as mismatch negativity (MMN) and P3a using the passive oddball paradigm have been studied in children and adolescents with ADHD. Still, there is no such data for adults with ADHD. This study aimed to compare the MMN and P3a and their clinical and neurocognitive correlations between drug-naive adults with ADHD and control adults.

Methods: We recruited 52 adults with ADHD (26.5 ± 6.2 years), and 62 age-matched controls (25.6 ± 5.6 years). They received the psychiatric interviews, auditory ERP, the Conners' continuous performance test (CCPT), and the Cambridge gambling test (CGT). They also completed the questionnaires about ADHD symptoms and real-world executive functions. MMN and P3a were assessed during a passive duration-deviant auditory oddball paradigm from the midline electrodes Cz.

Results: Adults with ADHD demonstrated smaller Cz MMN amplitude, more severe ADHD symptoms, poorer attention profiles (CCPT), and a wide range of executive dysfunctions than controls. As for the correlates, Cz peak amplitude of MMN correlated with inattention symptoms, executive dysfunctions, attentional vigilance (CCPT), and decision-making (CGT) in ADHD adults but only with decision-making in controls.

Conclusions: Our findings that smaller amplitude of MMN and its differential associated pattern with inattention, real-world executive dysfunction, and decision-making, in drug-naive adults with ADHD from adult controls, provide evidence to support the potential electrophysiological biomarker for adult ADHD.

Titel:	Mismatch negativity and P3a in drug-naive adults with attention-deficit hyperactivity disorder.
Autor/in / Beteiligte Person:	Hsieh, MH ; Chien, YL ; Gau, SS
Link:	Full Text Finder (Volltext)
Zeitschrift:	Psychological medicine, 2021-03-12, S. 1-11
Veröffentlichung:	Ahead of Print, 2021
Medientyp:	academicJournal
ISSN:	1469-8978 (electronic)
DOI:	10.1017/S0033291720005516
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Psychol Med] 2021 Mar 12, pp. 1-11. <i>Date of Electronic Publication: </i>2021 Mar 12. References: Neuropsychiatr Dis Treat. 2016 Dec 12;12:3183-3190. (PMID: 28003754) ; Int J Neuropsychopharmacol. 2013 Oct;16(9):1959-73. (PMID: 23672818) ; Psychol Med. 2021 Mar;51(4):579-586. (PMID: 31769374) ; Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):95-9. (PMID: 17764800) ; Schizophr Bull. 2016 Nov;42(6):1504-1516. (PMID: 27217271) ; J Pediatr Psychol. 2009 Sep;34(8):850-61. (PMID: 19074488) ; Neuropsychology. 2013 May;27(3):287-302. (PMID: 23688211) ; Biol Psychol. 1979 Mar;8(2):81-136. (PMID: 465623) ; J Child Psychol Psychiatry. 2013 Sep;54(9):996-1004. (PMID: 23574361) ; Biol Psychol. 1996 Apr 12;43(2):163-85. (PMID: 8805970) ; Front Psychiatry. 2019 Apr 15;10:223. (PMID: 31037058) ; Epidemiol Psychiatr Sci. 2019 Jan 30;29:e15. (PMID: 30696515) ; Brain Topogr. 2017 May;30(3):343-351. (PMID: 28054159) ; Psychiatry Res Neuroimaging. 2016 Mar 30;249:57-66. (PMID: 27000308) ; J Child Psychol Psychiatry. 1996 Jan;37(1):51-87. (PMID: 8655658) ; Neuropsychologia. 2013 Jan;51(2):211-9. (PMID: 23022080) ; Psychiatry Res. 2014 Aug 30;218(3):356-8. (PMID: 24814139) ; Neurosci Lett. 2016 Jan 26;612:132-137. (PMID: 26628248) ; Psychol Med. 2019 May;49(7):1195-1206. (PMID: 30642411) ; Neurosci Lett. 2005 Feb 21;374(3):212-7. (PMID: 15663965) ; Psychopharmacol Bull. 1993;29(2):229-33. (PMID: 8290670) ; Bipolar Disord. 2014 Sep;16(6):592-9. (PMID: 24807680) ; Wellcome Open Res. 2019 Apr 1;4:63. (PMID: 31069261) ; Front Hum Neurosci. 2015 Aug 26;9:470. (PMID: 26379533) ; Curr Protoc Neurosci. 2010 Jul;Chapter 6:Unit 6.25.1-24. (PMID: 20578033) ; Acta Psychiatr Scand. 2007 Aug;116(2):129-36. (PMID: 17650275) ; Clin Neurophysiol. 2007 Aug;118(8):1855-65. (PMID: 17576093) ; Int J Methods Psychiatr Res. 2008;17(1):35-44. (PMID: 18286459) ; J Int Neuropsychol Soc. 2013 Jul;19(6):686-94. (PMID: 23462256) ; PLoS One. 2012;7(4):e34454. (PMID: 22496807) ; J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168-79. (PMID: 11211365) ; J Atten Disord. 2020 Jan;24(1):29-40. (PMID: 28895460) ; J Atten Disord. 2010 Jan;13(4):347-57. (PMID: 19448149) ; Clin Neurophysiol. 2009 Mar;120(3):453-63. (PMID: 19181570) ; Eur Arch Psychiatry Clin Neurosci. 2000;250(2):101-10. (PMID: 10853926) ; Am J Psychiatry. 2006 Oct;163(10):1730-8. (PMID: 17012683) ; Audiol Neurootol. 2000 May-Aug;5(3-4):151-66. (PMID: 10859410) ; Psychol Med. 2017 Jan;47(2):377-388. (PMID: 27776572) ; Clin Neurophysiol. 2018 Sep;129(9):1899-1906. (PMID: 30005217) ; J Atten Disord. 2017 Jan;21(2):100-109. (PMID: 24203774) ; Acta Psychol (Amst). 1978 Jul;42(4):313-29. (PMID: 685709) ; Clin Neurophysiol. 2009 Nov;120(11):1883-1908. (PMID: 19796989) ; Psychol Med. 1998 Jul;28(4):773-88. (PMID: 9723135) ; Biol Psychol. 2016 Apr;116:68-74. (PMID: 26582536) ; Arch Clin Neuropsychol. 2010 May;25(3):157-73. (PMID: 20197297) ; C R Acad Sci III. 1998 Feb-Mar;321(2-3):167-73. (PMID: 9759336) ; PLoS One. 2013 Sep 13;8(9):e74909. (PMID: 24058638) ; J Neurosci. 2012 Mar 14;32(11):3665-78. (PMID: 22423089) ; Annu Int Conf IEEE Eng Med Biol Soc. 2016 Aug;2016:4662-4665. (PMID: 28325011) ; J Atten Disord. 2021 May;25(7):989-1000. (PMID: 31583930) ; Int J Psychophysiol. 2019 Nov;145:5-14. (PMID: 30831138) ; Cortex. 2005 Jun;41(3):377-88. (PMID: 15871602) ; Aust N Z J Psychiatry. 2016 Jun;50(6):548-56. (PMID: 26460330) ; J Child Adolesc Psychopharmacol. 2012 Oct;22(5):353-63. (PMID: 23083022) ; Schizophr Res. 2012 Sep;140(1-3):243-9. (PMID: 22784684) ; Eur Arch Psychiatry Clin Neurosci. 2010 Aug;260(5):427-40. (PMID: 19907927) ; Psychol Med. 2019 Apr;49(6):940-951. (PMID: 29941053) ; Arch Gen Psychiatry. 1995 Jul;52(7):550-8. (PMID: 7598631) ; Psychol Med. 2015 Feb;45(3):529-43. (PMID: 25075643) ; Biol Psychiatry. 2006 Nov 15;60(10):1081-7. (PMID: 16876139) ; Psychol Bull. 1997 Jan;121(1):65-94. (PMID: 9000892) ; Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1841-5. (PMID: 21839796) ; Psychiatry Clin Neurosci. 2010 Oct;64(5):491-8. (PMID: 20923428) ; Brain Res. 2016 Feb 1;1632:42-50. (PMID: 26688114) ; Res Dev Disabil. 2013 Oct;34(10):3168-81. (PMID: 23886759) ; Clin Neurophysiol. 2007 Dec;118(12):2544-90. (PMID: 17931964) ; Nat Rev Dis Primers. 2015 Aug 06;1:15020. (PMID: 27189265) ; Child Neuropsychol. 2000 Sep;6(3):235-8. (PMID: 11419452) ; Int J Psychophysiol. 2009 Oct;74(1):19-27. (PMID: 19607863) ; Med Hypotheses. 2012 Jun;78(6):802-10. (PMID: 22520337) ; J Neurosci. 1999 Oct 15;19(20):9029-38. (PMID: 10516320) ; Am J Psychiatry. 2005 Jul;162(7):1344-50. (PMID: 15994718) ; Arch Gen Psychiatry. 1978 Jul;35(7):837-44. (PMID: 678037) ; Brain Topogr. 1990 Fall;3(1):137-41. (PMID: 2094301) ; Neuroimage. 2013 Feb 1;66:594-603. (PMID: 23085112) Contributed Indexing: Keywords: Adult ADHD; P3a; drug-naive; mismatch negativity; neurophysiological marker Entry Date(s): Date Created: 20210312 Latest Revision: 20240222 Update Code: 20240223 PubMed Central ID: PMC9772912

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Mismatch negativity and P3a in drug-naive adults with attention-deficit hyperactivity disorder.